Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Metastatic Castration-sensitive Prostate Cancer 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Diseases 1Graft vs Host Disease 1Burkitt Lymphoma 1

Interventions

Vincristine 1Prednisone 1Doxorubicin 1Cyclophosphamide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Lymphoma, T-Cell × Prednisone × Clear all
NCT01777152 2021-11-30

ECHELON-2

Seagen Inc.

Phase 3 Completed
452 enrolled 16 charts 1 FDA
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡